PropertyValue
?:abstract
  • Drugmakers Incyte and Novartis are gearing up for a Phase III clinical trial of their drug ruxolitinib to see if it can help patients with severe COVID-19, the respiratory disease caused by the new coronavirus Doctors think the compound might dampen the out-of-control immune response—known as a cytokine storm—seen in people with severe COVID-19 If the cytokine storm can be tempered before there is significant damage to the lungs, patients might not require ventilators or might need them for less time and have a better chance of surviving the disease Plans for the randomized trial were announced April 2 The trial will compare the outcomes of about 350 hospitalized patients who get either ruxolitinib or the current best standard of care without the drug Severe COVID-19 patients unable to enroll in a trial can still get the drug through a so-called open-label study, in which both the doctor and patient
?:creator
?:journal
  • C&EN_Global_Enterprise
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Ruxolitinib to be tested in fight against COVID-19
?:type
?:who_covidence_id
  • #48050
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/hbu6ixqy>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/hbu6ixqy>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all